Rigel Pharmaceuticals, Inc. (RIGL)
Rigel Pharmaceuticals, Inc. (RIGL) Soars to 52-Week High, Time to Cash Out?
Rigel (RIGL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Overlooked Stock: RIGL Nearly Doubles Stock in August
Rigel Pharmaceuticals (RIGL) is up 88% in August and more than tripled its stock price over the last year. The staggering upside rally began with a massive earnings beat and raised guidance.
Rigel Pharmaceuticals: Q2 Earnings Fuel A Potential Breakout
Rigel's Q2 results were outstanding, with revenue nearly doubling and net income surging, driven by strong commercial momentum for TAVALISSE, GAVRETO, and REZLIDHIA. Management raised 2025 guidance, expecting positive net income and robust sales growth, signaling Rigel's transition to a self-sustaining, growth-focused biotech. Pipeline progress, especially with R289 and REZLIDHIA label expansion, offers long-term catalysts, but investors must weigh risks from nonrecurring revenue and clinical execution.
Earnings Estimates Moving Higher for Rigel (RIGL): Time to Buy?
Rigel Pharmaceuticals (RIGL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Rigel Pharmaceuticals (RIGL) Just Flashed Golden Cross Signal: Do You Buy?
From a technical perspective, Rigel Pharmaceuticals, Inc. (RIGL) is looking like an interesting pick, as it just reached a key level of support. RIGL's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.
Rigel Pharmaceuticals, Inc. (RIGL) Hits Fresh High: Is There Still Room to Run?
Rigel (RIGL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Rigel Pharmaceuticals, Inc. (RIGL) Q2 2025 Earnings Call Transcript
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants David A. Santos - Executive VP & Chief Commercial Officer Dean L.
Rigel Pharmaceuticals (RIGL) Q2 Earnings and Revenues Surpass Estimates
Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $3.28 per share, beating the Zacks Consensus Estimate of $1.97 per share. This compares to a loss of $0.06 per share a year ago.
Why Rigel (RIGL) Could Beat Earnings Estimates Again
Rigel (RIGL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Can Rigel (RIGL) Climb 69.55% to Reach the Level Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 69.6% in Rigel (RIGL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Are Investors Undervaluing Rigel Pharmaceuticals (RIGL) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Rigel Pharmaceuticals (RIGL) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
